Quantcast

Latest Monoclonal antibodies Stories

2014-05-20 20:22:08

DEERFIELD, Ill. and OSAKA, Japan, May 20, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio((TM)) (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). ( ) "Entyvio is a new option that...

2014-05-20 16:26:30

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA(®) (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical...

2014-05-19 16:24:15

NEUDORF SPECIAL ECONOMIC ZONE, ST. PETERSBURG, Russia, May 19, 2014 /PRNewswire/ -- Head of the Russian Government Dmitri Medvedev visited today CJSC BIOCAD's [http://www.biocad.ru/en/we ] commercial manufacturing facility for mAb-based therapeutic proteins. This private facility is unique in Russia and Easter Europe. It produces monoclonal antibodies-based APIs for biological products that are widely used in treating oncological and autoimmune disorders. The visit occurred in...

2014-05-19 08:29:14

PASADENA, Calif., May 19, 2014 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-drug conjugates (ADC) using its proprietary monoclonal antibody (mAb) technology platform, today announced the appointment of C. Dan Dumitru, M.D., Ph.D., as Vice President of Translational Research. "We are delighted to expand our highly focused team to include Dan, who brings a strong background in preclinical and translational drug development for biologics...

2014-05-19 08:28:15

HERZLIYA, Israel, May 19, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of consultants Lee S. Simon, MD, FACP, FACR and David Isenberg, MD, for the planned Phase II trial for the Company's hCDR1 compound for the treatment of...

2014-05-17 23:01:11

ReportsnReports.com offers "Antibody Drug Conjugate Market Opportunity Analysis" report to its research database. The global ADC market would grow at a CAGR of more than 40% to reach USD 6.8 billion by 2020. Dallas, Texas (PRWEB) May 17, 2014 Ever since the first attempt in the 1980s to use antibody based drugs as therapeutic agents, the application and use of monoclonal antibody-drug conjugates has evolved in several ways. The major advantage of using Antibody Drug Conjugates...

2014-05-16 08:25:52

CAMBRIDGE, England, May 16, 2014 /PRNewswire/ -- Series B Financing includes the Wellcome Trust and the Bill & Melinda Gates Foundation Kymab, a monoclonal antibody biopharmaceutical company, announced today it has successfully raised US$40 million in a Series B financing. The Bill & Melinda Gates Foundation joins existing investor, the Wellcome Trust, each investing US$20 million. The funds will enable Kymab to maximise the potential of its Kymouse(TM)...

2014-05-15 08:32:10

Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma MONROVIA, Calif., May 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced it will present preclinical data comparing activity of XmAb®7195 to omalizumab in reducing IgE, a protein responsible...

2014-05-14 16:28:04

Conference call today at 4:30 p.m. EDT MONROVIA, Calif., May 14, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the first quarter ended March 31, 2014 and provided a review of recent business highlights. "We have continued to advance our drug development programs and we plan to have...

2014-05-14 12:31:58

LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmapoint_crohns_disease_global_drug_forecast_market_analysis_2022.htmlPharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022SummaryThe Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'